Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
OBJECTIVE
To assess the effect of ergot derivatives on cardiac valves in patients with Parkinson's disease (PD).


METHODS
Echocardiography was performed on 46 PD patients who used either pergolide or cabergoline (MonoPD) or both (MixPD) for a minimum of 1 year and 49 age-matched healthy controls. Valvular regurgitation was graded as mild, moderate and severe. MonoPD and MixPD groups were compared with regard to demographic features, drug profile and valvulopathy.


RESULTS
The PD group had a mean age of 63 years, agonist duration of 3.8 years and agonist equivalent dose of 3.5mg/day. Moderate regurgitation in all three valves was significantly more common in the PD group than the controls. Severe valvular regurgitation was not observed in either group, with the exception of one PD patient. The frequency of valvulopathy and doses of agonists did not differ between MixPD and MonoPD groups.


CONCLUSIONS
PD patients on dopamine ergot agonists are prone to moderate valvular regurgitation more than age-matched controls. However, the frequency of valvulopathy was similar in patients who used either one or more agonists.
Kenangil
Gülay
G
Department of Neurology, Education and Research Hospital of Sisli Etfal, 34360 Istanbul, Turkey.
Ozekmekçi
Sibel
S
Koldas
Lale
L
Sahin
Taylan
T
Erginöz
Ethem
E
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001022:Aortic Valve Insufficiency / Q000139:chemically induced / Q000175:diagnosis; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004452:Echocardiography / Q000187:drug effects; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D014262:Tricuspid Valve Insufficiency / Q000139:chemically induced / Q000175:diagnosis
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004873:Ergolines; D010479:Pergolide; D000077465:Cabergoline